Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

@article{Alvn1990HydroxylationPO,
  title={Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations},
  author={Gunnar Alv{\'a}n and Paul Bechtel and Lennart Iselius and Ursula M. Gundert-Remy},
  journal={European Journal of Clinical Pharmacology},
  year={1990},
  volume={39},
  pages={533-537}
}
European data on the polymorphic metabolism of debrisoquine, sparteine, dextromethorphan and mephenytoin have been collected. No significant difference in phenotype frequencies was found between the separate series for debrisoquine, sparteine and dextromethorphan, which supports the claim that these probe drugs reflect the same enzyme polymorphism. The mean frequency of the phenotype slow debrisoquine metaboliser was 7.65% based on 5005 determinations. The overall mean reflecting all three… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 110 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Ethnic differences in drug disposition

  • L Bertilsson
  • KK (eds) Topics in Pharmaceutical Sciences
  • 1989
Highly Influential
2 Excerpts

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

  • K BrOsen, LF Gram
  • Eur J Clin Pharmacol
  • 1989

Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a cocktail approach

  • DD Breimer, JHM Schellens, PA Soons
  • M (eds)Proceedings of the VIIth International…
  • 1988

Hydroxylation polymorphisms of debrisoquine xylation phenotype does not predict the metabolism of phenytoin

  • E Steiner, L Bertilsson, J Sgwe, I Bertling
  • 1988

Similar Papers

Loading similar papers…